Form 4 for GENB Generate Biomedicines, Inc.
Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-26 · accession 0001193125-26-085883 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-03-02 | 2026-03-02 | GENB | Nally Michael | CEO, Dir | C - Cnv Deriv | — | +658.3K | 1.32M | +100% | — |
| DM | 2026-03-02 | 2026-02-26 | GENB | Nally Michael | CEO, Dir | A - Grant | $0.00 | +1.69M | 844.6K | New | $0 |
| DI | 2026-03-02 | 2026-03-02 | GENB | Nally Michael | CEO, Dir | C - Cnv Deriv | $0.00 | -1.00M | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | C | A | 658,327 | — | 1,316,654 | I By MTN 2024 GST Trust | — | — | (F1) Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. (F2) The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-02-26 | A | A | 844,595 | $0.00 | 844,595 | D By MTN 2024 GST Trust | $16.00 · — to 2036-02-25 | 844,595 Common Stock | (F2) The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. (F3) The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date. |
| 3 | Derivative | Series A Preferred Stock | 2026-03-02 | C | D | 1,000,000 | $0.00 | 0 | I | — · — to — | 658,327 Common Stock | (F1) Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-02-26 | A | A | 844,595 | $0.00 | 844,595 | D | $16.00 · — to 2036-02-25 | 844,595 Common Stock | (F4) The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. |